Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: The Jackson Laboratory, Biocept, and More

NEW YORK (GenomeWeb) – The Jackson Laboratory announced this week that it has signed an agreement with Crown Bioscience to develop innovative research models and provide preclinical services to the biomedical research community. As part of the agreement, CrownBio will advance the use of Jax mice in client research studies and increase the utilization of Jax research models. Jax research scientists will have select access to CrownBio’s preclinical contract laboratory services.


Biocept this week signed an agreement making its Target Selector liquid biopsy tests available through MediNcrease’s client base of regional and national health plans, insurance firms, employers, municipalities, third-party administrators, unions, and other companies managing medical claims.


Transgenomic said this week that it is advancing its previously announced plans for relisting on the Nasdaq. The company implemented a reverse split of its shares on June 13 in order to meet Nasdaq relisting requirements of a closing share price at or above $4 for five consecutive trading days. The company said it believes that its merger with Precipio Diagnostics, which is expected to be completed in the next few days, will result in an entity that satisfies the Nasdaq relisting requirements.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.